GlassScriptPhysician profile
Shweta Arora
NPI 1841447000
$3,922.56
in general payments reported to CMS, 2019-2025
41 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.44 · 2020: $54.74 · 2021: $86.95 · 2022: $385 · 2023: $969 · 2024: $1,149 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,306 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,306.03 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $577.88 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $453.23 | 2021-2025 | Vraylar, Mavyret |
| Pfizer INC. | $429.84 | 2020-2025 | |
| Lilly USA, LLC | $335.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $296.06 | 2022-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Abbott Laboratories | $161.92 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $148.04 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $143.42 | 2019-2025 | Repatha, Otezla, Otezla |
| Shield Therapeutics INC | $112.12 | 2023-2024 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $104.68 | 2019-2024 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $89.01 | 2024-2025 | |
| Exact Sciences Corporation | $88.02 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $86.14 | 2024-2025 | Zenpep |
| Sanofi Pasteur INC. | $83.86 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.37 | 2022-2024 | Stiolto Respimat, Spiriva Respimat, Jardiance |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shweta Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.